AI-READI: rethinking AI data collection, preparation and sharing in diabetes research and beyond
Competing pursuits
S.B.: funding — NIH, College of California Workplace of the President, Analysis to Forestall Blindness; guide — Topcon; tools — Optomed. V.R.d.S.: funding — NSF, UCSD Social Sciences, Sanford Institute for Empathy and Compassion (Heart for Empathy and Know-how), Intel, Mathworks, UCSD tutorial enchancment grant, tools funding from Adobe and NVIDIA, Kavli Institute for Mind and Thoughts, IBM, previous funding from Sony; member — Cognitive Science Society Governing Board. Ok.F.: member — Institutional Evaluation Board for the All of Us Analysis Program, Digital Ethics Advisory Panel for Merck KGaA (Merck Germany). C.S.L.: funding — NIH, Alzheimer’s Illness Drug Discovery Basis, Gates Ventures, Analysis to Forestall Blindness. T.Y.A.L.: funding — Analysis to Forestall Blindness, Dr. H. James and Carole Free Profession Improvement Award. B.P.: funding — NIH. L.M.Z: funding — NEI, NIH, The Glaucoma Basis, Heidelberg Engineering, DRCR Retina Community/JAEB Heart for Well being Analysis, The Krupp Basis; receipt of apparatus, supplies, software program — Optomed, ICare, Topcon, Heidelberg Engineering, Carl Zeiss Meditec, Optovue/Visionix; guide — Abbvie, Topcon Medical Techniques; co-founder, inventor, board member, fairness holder — AISight Well being Inc. S.H.: funding — NIH, NIH/NARCH, RWJF, UCSD Herbert Wertheim College of Public Well being. H.I.: funding — NIH; founder, inventory holder — Gobiquity, Inc. A.Y.L.: funding — Santen, Topcon, Carl Zeiss Meditec, Regeneron, Amazon, Meta, Analysis to Forestall Blindness; private charges — Genentech, Sanofi, US FDA, Johnson and Johnson, Boehringer Ingelheim, Gyroscope; non-financial help — iCareWorld, Optomed, Heidelberg, Microsoft. S.M.: Funding — NIH, Edward P. Evans Basis, OHSU Knight Most cancers Institute; receipt of in-kind contribution — Nike. C.N.: funding — NIH, NSF, PCORI. C.O.: guide — Johnson and Johnson. L.H.: funding — NIH Grant UL1TR001442; guide — Bristol Myers Squibb. The remaining authors declare no competing pursuits.
